Browse > Article

The Prospective of Antigen-presenting Cells in Cancer Immunotherapy  

Shim Doo-Hee (Department of Bioscience and Biotechnology, College of Engineering, Silla University)
Lee Jae-Hwa (Department of Bioscience and Biotechnology, College of Engineering, Silla University)
Publication Information
KSBB Journal / v.19, no.6, 2004 , pp. 415-420 More about this Journal
Abstract
All around the world, the rate of attack of cancer diseases has been going up and the number of cancer patients has been increasing every year. Cancer can be divided into malignant tumor and benign tumor according to its growth appearance. Many studies and experiments have been conducted and the various treatment are being created to find the way to care malignant. Dendritic cells (DCs), which is an agent of cancer treatments by using an immune reaction in our body, plays an important role to present by a tumor antigen to cytotoxic T-cell and help them to attack the tumor cell directly. However there are some defects of this therapy. Soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) based artificial antigen presenting cell (aAPC) as the antigen presenting cell (APC) which is complement and overcome some of the limitations of dendritic cell-based vaccines and ex vivo expansion of human T cells is new method for cancer therapy. In this article, we are reviewing the role of DCs and the treatment with it, and searching for the possibility of the new development of immunotherapy for cancer.
Keywords
Dendritic cell; immunotherapy; cancer; vaccine;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Antonia, S., J. J. Mule, and S. Weber (2004), Current developments of immunotherapy in the clinic, Curr. Opin. Immunol. 16, 1-7
2 Pulendran, B., K. Palucka, and J. Banchereau (2001), Sensing pathogenes and tuning immune responses, Science 293(5528), 253-256
3 Jefford, M., E. maraskovsky, J. Cebon, and I. D. Davis (2001), The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343-353
4 Hwang, J. W., M. Kim, K. Kim (1998), T cell epitope analysis of structural protein of adenovirus, Kor. J. Immunol. 20(4), 435-442
5 Kjaergaard, J., K. Shimizu, and S. Shu (2003), Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine, Cell. Immunol. 255, 65-74
6 Thumann, P. I. Moc and L. Jenne et al. (2003), Antigen loading of dendritic cells with whole tumor cell preparations, J. Immunol. Methods 277, 1-16
7 Ruffini, P. A. and L. W. Kwak (2001), Immunotheraphy of multiple myeloma, Semin. Hematol. 38, 260-267
8 Bella, S. D. et al. (2003), Altered maturation of peripheral blood dendritic cells in patients with breast cancer, Br. J. cancer. 89, 1463-1472
9 Krueger, C. et al. (2004), Quality and quantity: new strategies to improve immunotherapy of cancer, TRENDS in Mol. Med. 10(5), 205-208
10 Wick, M. et al. (1997), Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy, J. Exp. Med. 186(2), 229-238
11 Steinman, R. M. and M. Pope (2002), Exploiting dendritic cells to improve vaccine efficacy, J. Clin. Invest. 109(12), 1519-1526
12 Jung, S. (2004), Good, Bed and beautiful-the role of dendritic cells in autoimmunity, Autoimmunity Rev. 3, 54-60
13 Martins, M. T. and A. L. Witzel, et al. (2004), Dendritic cell sarcoma of the oral cavity, Oral. Oncol. 40, 341-347
14 Nastle, F. O., S. Alijagic, and M. Gilliet et al. (1998), Vaccination of melanoma patients with peptide- or tumor-lysate plused dendritic cells, Nat. Med. 4, 328-332
15 Bae, J. M. and J. P. Kim (1998), Effect of adjuvant immunochemotherapy on immunologic function of gastric cancer patients, Kor. Sur. Society 55(2), 190-197
16 Banchereau. J. and R. M. Steinman (1998), Dendritic cells and the control of immunity, Nature 392, 245-252
17 Yan, X., B. D. Johnson, and R. J. Orentas (2004), Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expression on neuroblastoma expands CD8 tumor-reactive effector cells in vivo, Immunology 112(1), 105-116
18 May, K. F., Jr., L. Chen, P. Zheng, and Y. Lui (2002), Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by priming survival but not clonal expansion of tumor-specific CD8+ T cells, Cancer Res. 62, 3459-3465
19 Banchereau, J., R. M. Steinman (1998), Dendritic cells and the control of immunity, Nature 392, 245-252
20 Dallal, R. M. and M. T. Lotze (2000), The dendritic cell and human cancer vaccines, Curr. Opin. Immunol. 12, 583-588
21 Bozza, S. and L. Romani et al. (2004), Dendritic cell-based vaccination against opportunistic fungi, Vaccine 22, 857-864
22 Finn, O. J. (2004), Tumor immunology Tumor immunology at the service of cancer immunotherapy, Curr. Opin. Immunol. 16, 1-3
23 Boon, T. and B. V. Eynde (2003), Tumor Immunology, Curr. Opin. Immunol. 15, 129-130
24 Belli, F. et al. (2002), Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings, J. Clin. Oncol. 20(20), 4169-4180
25 Hsueh, E. C., R. K. Gupta, K. Qi, D. L. Morton (1998), Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine, J. Clin. Oncol. 16, 2913-2920
26 Yuji, T., T. Masatoshi et al. (2003), T-cell-dependent antitumor effects produced by CD40 ligand expressed on mouse lung carcinoma cells are linked with the maturation of dendritic cells and secretion of a variety of cytokines, Cancer Gene Ther. 10, 451-456
27 Maus, M. V., J. L. Riley, and C. H. June et al. (2003), HLA teramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells, Clin. Immunol. 106, 16-22
28 Orchard, P. J. et al. (2002), Clinical-scale selection of anti-CD3 /CD28-activated T cells after transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor, Hum. Gene Ther. 13(8), 979-988
29 International Agency for Research on Cancer-WHO. Cancer research for cancer control. IARC, Lyon, France, 2001
30 Suh, H. S. and M. D. (1993), The Role of Radiation Therapy in Cancer Management, Inje. Med. J. 4(3), 253-258
31 Singh, M. and D. O'Hagan (1999), Advances in vaccine adjuvants, Nat. Biotechnol. 17, 1075-1081
32 Schijins, V. E. (2000), Immunological concepts of vaccine adjuvant activity, Curr. Opin. Immunol. 12, 456-463
33 Yoo, K. Y. and H. R. Shin (2003), Cancer Epidemiology and Prevention, Kor. J. Epidem. 25(1), 1-15
34 O'Doherty, U. et al. (1994), Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature, Immunology 82, 878-884
35 Oleike, M. et al. (2003), Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells, Nature 9(5), 619-625
36 Enk, A. H., H. Jonuleit, J. Saloga, and J. Knop (1997), Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma, Int. J. Cancer. 73(3), 309-316
37 Lee, P. P. et al. (1999), Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Med. 5, 677-685
38 Terabe, M. and J. A. Berzofsky (2004), Immunoregulatory T cells in Tumor Immunity, Curr. Opin. Immunol. 16, 1-6
39 Gunzer, M. et al. (2001), Dendritic cells and tumor immunity immunology, Immunology 13, 291-302
40 Carbone, F. R. and W. R. Heath (2003), The role of dendritic cell subsets in immunity to virus, Curr. Opin. Immunol. 15, 416-420
41 Ratta, M. et al. (2002), Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6, Blood 100, 230-237
42 Knuth, A., T. Wolfel, and E. Klemann et al. (1989), Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection, Proc. Natl. Acad. Sci. USA 86(8), 2804-2808
43 Soiffer, R. et al. (2003), Vaccination With Irradiated, Autologous Melanoma Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor by Adenoviral-Mediated Gene Transfer Augments Antitumor Immunity in Patients With Metastatic Melanoma, J. Clin. Oncol. 21(17), 3343-3350
44 Finn, O. J. (2003), Cancer vaccines: between the idea and the reality, Nat. Rev. Immunol. 3(8), 630-641
45 Sadanaga, N. et al. (2001), Dendritic cell vaccination with MAGE peptides is a novel therapeutic approach for gastrointestinal carcinomas, Clin. Cancer. Res. 7, 2277-2284